Aastrom Biosciences initiates treatment in Stage 2 catheter-based clinical trial for dilated cardiomyopathy Aastrom Biosciences, Inc http://aygestin.org . , the leading programmer of autologous cellular treatments for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the business’s U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy . Henry, M.D. This potential, randomized, controlled, multi-center clinical trial is made to determine the safety and tolerability of Aastrom’s tissue fix cells , administered via catheter, in the treating patients with heart failure because of DCM. The trial seeks to sign up 12 ischemic DCM and 12 non-ischemic DCM patients.
The IMPRESS study was made to compare the safety and efficacy of continuing IRESSA, combined with cisplatin and pemetrexed up to six cycles , versus comparator placebo, coupled with cisplatin and pemetrexed up to six cycles following a development of resistance to first series treatment gefitinib. The study didn’t meet its principal endpoint of a statistically significant improvement in PFS. The secondary endpoint of general survival is still ongoing. At the primary endpoint of PFS analysis, the OS was immature and had not been conclusive. Longer OS was suggested for the placebo plus cisplatin and pemetrexed arm, versus the IRESSA plus cisplatin and pemetrexed arm.